COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISK

被引：0
作者：
Garcia-Goni, M. [1 ]
Facila, L. [2 ]
Cinza, S. [3 ]
Pinto, X. [4 ]
Cortes, X. [5 ]
Prades, M. [6 ]
Aceituno, S. [6 ]
机构：
[1] Univ Complutense, Madrid, Spain
[2] Hosp Gen Univ Valencia, Valencia, Spain
[3] Porto Do Son Primary Care Hlth Ctr, La Coruna, Spain
[4] Hosp Bellvitge Princeps Espanya, Lhospitalet De Llobregat, Spain
[5] Almirall SA, Barcelona, Spain
[6] Outcomes 10, Castellon De La Plana, Spain
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.620
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV74
引用
收藏
页码：S104 / S105
页数：3
相关论文
共 50 条
[41]   Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain [J].
Arrospide-Elgarresta, Arantzazu ;
Mar, Javier ;
Vivancos-Mora, Jose ;
Rejas-Gutierrez, Javier ;
Caro, Jaime .
REVISTA DE NEUROLOGIA, 2010, 51 (01) :1-11
[42]   Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk [J].
Laufs, Ulrich ;
Karmann, Barbara ;
Pittrow, David .
CLINICAL RESEARCH IN CARDIOLOGY, 2016, 105 (09) :783-790
[43]   Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk [J].
Ulrich Laufs ;
Barbara Karmann ;
David Pittrow .
Clinical Research in Cardiology, 2016, 105 :783-790
[44]   Atorvastatin Therapy in Practice- LDL Values in Patients with very high Cardiovascular Risk [J].
Laufs, Ulrich ;
Jannowitz, Christina ;
Pittrow, David .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2017, 142 (16) :1249-1252
[45]   Cost-Effectiveness Analysis of Evolocumab Therapy in Patients at High Risk of Cardiovascular Events in the Context of the Brazilian Unified Health System [J].
Latado, Luiza ;
Vieira de Melo, Rodrigo Morel ;
Mistro, Sostenes ;
Latado, Adriana Lopes ;
do Nascimento, Harrison Floriano ;
Lira, Yasmin Menezes ;
Cardoso de Oliveira, Natalia Ferreira ;
Galindo, Yuri de Santana ;
Viana, Taina ;
Santana Passos, Luiz Carlos .
ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2021, 117 (05) :988-996
[46]   Cost-effectiveness of baloxavir marboxil compared with laninamivir for the treatment of influenza in patients at high risk for complications in Japan [J].
Dronova, Mariia ;
Ikeoka, Hidetoshi ;
Itsumura, Naoya ;
Hirotsu, Nobuo ;
Ansaripour, Amir ;
Aballea, Samuel ;
Onishi, Yoshie ;
Hill, Mark ;
Igarashi, Ataru .
CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (07) :1135-1148
[47]   Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: A cost-effectiveness analysis [J].
Hershman, D ;
Sundararajan, V ;
Jacobson, JS ;
Heitjan, DF ;
Neugut, AI ;
Grann, VR .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :9-16
[48]   Efficacy and Safety of High Intensity Atorvastatin in Patients With Acute Myocardial Infartion Compared to High Intensity Rosuvastatin [J].
Choi, Cheol Ung ;
Choi, Jah Yeon ;
Choi, Byoung Geol ;
Park, Yoonjee ;
Kang, Dong Oh ;
Jang, Won Young ;
Kim, Woohyeun ;
Roh, Seung-young ;
Na, Jin Oh ;
Kim, Jin Won ;
Kim, Eung Ju ;
Rha, Seung Woon W. ;
Park, Chang Gyu ;
Seo, Hong Seog ;
Jeong, Myung Ho .
CIRCULATION, 2019, 140
[49]   COST-EFFECTIVENESS OF LDL-C LOWERING WITH EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN THE UNITED STATES [J].
Gandra, S. R. ;
Villa, G. ;
Fonarow, G. ;
Lothgren, M. ;
Lindgren, P. ;
Somaratne, R. ;
van Hout, B. .
VALUE IN HEALTH, 2016, 19 (03) :A3-A3
[50]   Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States [J].
Gandra, Shravanthi R. ;
Villa, Guillermo ;
Fonarow, Gregg C. ;
Lothgren, Mickael ;
Lindgren, Peter ;
Somaratne, Ransi ;
van Hout, Ben .
CLINICAL CARDIOLOGY, 2016, 39 (06) :313-320
12345